CLINICAL TRIALS PROFILE FOR SODIUM IODIDE I-123

All Clinical Trials for SODIUM IODIDE I-123

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00638092 ↗	A Randomised Controlled Trial of Iodide Supplementation in Preterm Infants Follow-up at 2 Years	Completed	National Institute for Health Research, United Kingdom	Phase 4	2010-03-01	The purpose of this trial is to determine whether iodide supplementation of neonates born under 31 weeks gestation improves neurodevelopment measured at two years of age.
NCT00638092 ↗	A Randomised Controlled Trial of Iodide Supplementation in Preterm Infants Follow-up at 2 Years	Completed	University of Dundee	Phase 4	2010-03-01	The purpose of this trial is to determine whether iodide supplementation of neonates born under 31 weeks gestation improves neurodevelopment measured at two years of age.
NCT00638092 ↗	A Randomised Controlled Trial of Iodide Supplementation in Preterm Infants Follow-up at 2 Years	Completed	University of Oxford	Phase 4	2010-03-01	The purpose of this trial is to determine whether iodide supplementation of neonates born under 31 weeks gestation improves neurodevelopment measured at two years of age.
NCT00788307 ↗	Gene Therapy and Radioactive Iodine in Treating Patients With Locally Recurrent Prostate Cancer That Did Not Respond to External-Beam Radiation Therapy	Terminated	National Cancer Institute (NCI)	Phase 1	2008-11-03	RATIONALE: Radioactive drugs, such as radioactive iodine, may carry radiation directly to tumor cells and not harm normal cells. Placing a gene called Ad5CMV-NIS in prostate cancer cells may help the prostate cells take in more radioactive iodine and thus kill the cancer cells. Drugs, such as liothyronine sodium, may protect the thyroid from the side effects of radioactive iodine. PURPOSE: This phase I trial is studying the side effects and best dose of gene therapy given together with radioactive iodine in treating patients with locally recurrent prostate cancer that did not respond to external-beam radiation therapy.
NCT00725946 ↗	Pilot Study to Determine Radioiodide Accumulation and Dosimetry in Breast Cancers Using 124I PET/CT	Terminated	Stanford University	Early Phase 1	2008-02-01	This is a pilot imaging study for women whose tumors express NIS [Na+I- symporter, sodium iodide symporter]. Eligibility is limited to the presence of strong (3+) and/or plasma membrane staining in > 20% of cells as determined by immunohistochemical methods. A total of 10 patients will be imaged with 124I PET/CT (serial scans over 24 hour period) to determine radioiodide uptake and distribution in tumor tissue. Thyroid iodide uptake and retention will be blocked beginning one week prior to 124I PET/CT scan with thyroid hormone (T3) and methimazole (impedes organification). Tumor, organ and whole body dosimetry will be calculated in each patient.
NCT00450814 ↗	Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma	Completed	National Cancer Institute (NCI)	Phase 1/Phase 2	2006-11-30	This phase I/II trial studies the side effects and best dose of vaccine therapy when given with or without cyclophosphamide and to see how well they work in treating patients with multiple myeloma that has come back (recurrent) or has not responded to previous treatment (refractory). Vaccines made from a gene-modified virus may help the body build an effective immune response to kill cancer cells. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving vaccine therapy together with cyclophosphamide may be a better treatment for multiple myeloma.
NCT00450814 ↗	Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma	Completed	Mayo Clinic	Phase 1/Phase 2	2006-11-30	This phase I/II trial studies the side effects and best dose of vaccine therapy when given with or without cyclophosphamide and to see how well they work in treating patients with multiple myeloma that has come back (recurrent) or has not responded to previous treatment (refractory). Vaccines made from a gene-modified virus may help the body build an effective immune response to kill cancer cells. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving vaccine therapy together with cyclophosphamide may be a better treatment for multiple myeloma.

Clinical Trial Conditions for SODIUM IODIDE I-123

Condition Name

Condition Name for SODIUM IODIDE I-123
Intervention	Trials
Breast Cancer	4
Recurrent Plasma Cell Myeloma	2
Refractory Plasma Cell Myeloma	2
Ovarian Endometrioid Adenocarcinoma	2

Condition MeSH

Condition MeSH for SODIUM IODIDE I-123
Intervention	Trials
Breast Neoplasms	4
Neoplasms, Plasma Cell	3
Multiple Myeloma	3
Carcinoma	3

Clinical Trial Locations for SODIUM IODIDE I-123

Trials by Country

+

−

Trials by Country for SODIUM IODIDE I-123
Location	Trials
United States	13
United Kingdom	3
Canada	2
Korea, Republic of	2
Japan	1

Trials by US State

+

−

Trials by US State for SODIUM IODIDE I-123
Location	Trials
Minnesota	6
Florida	2
Arizona	2
California	2
Arkansas	1

Clinical Trial Progress for SODIUM IODIDE I-123

Clinical Trial Phase

Clinical Trial Phase for SODIUM IODIDE I-123
Clinical Trial Phase	Trials
Phase 4	3
Phase 2	4
Phase 1/Phase 2	3

Clinical Trial Status

Clinical Trial Status for SODIUM IODIDE I-123
Clinical Trial Phase	Trials
Recruiting	7
Terminated	4
Completed	4

Clinical Trial Sponsors for SODIUM IODIDE I-123

Sponsor Name

Sponsor Name for SODIUM IODIDE I-123
Sponsor	Trials
Mayo Clinic	6
National Cancer Institute (NCI)	5
Stanford University	2

Sponsor Type

Sponsor Type for SODIUM IODIDE I-123
Sponsor	Trials
Other	21
NIH	5
Industry	1

Sodium Iodide I-123: Clinical Trials, Market Analysis, and Projections

Introduction

Sodium iodide I-123 is a radiopharmaceutical that has been increasingly utilized in both diagnostic and therapeutic applications, particularly in the field of nuclear medicine. This article will provide an update on the current clinical trials, market analysis, and projections for sodium iodide I-123.

Clinical Trials Update

Diagnostic Imaging

Sodium iodide I-123 is primarily used in diagnostic imaging, especially for visualizing the thyroid gland. A key application is in thyroid scans, where I-123 allows healthcare professionals to diagnose various thyroid conditions such as nodules, goiters, and hyperthyroidism[2].

In a phase-1 clinical trial, high-specific-activity carrier-free I-123-iobenguane was tested in healthy adults. The study showed that this formulation had similar organ distribution and whole-body retention to conventional I-123-iobenguane, with improved heart-to-mediastinum ratios and varying radiation dosimetry estimations[3].

Therapeutic Applications

Beyond diagnostics, sodium iodide I-123 is also explored in conjunction with the sodium iodide symporter (NIS) for therapeutic purposes. NIS gene transfer allows cells to accumulate radioiodine, which can then be used to treat various cancers. For instance, in prostate cancer models, the combination of NIS gene transfer and I-131 therapy has shown significant tumor reduction[1].

In preclinical studies, NIS-mediated radioiodine accumulation has been effective in treating several types of cancer, including head and neck cancer, anaplastic thyroid cancer, glioma, pancreatic cancer, and ovarian cancer. These studies have demonstrated enhanced antitumor activity when I-131 is applied following NIS gene transfer[1].

Market Analysis

Current Market Size

The global sodium iodide market, which includes I-123, was valued at approximately $300 million in 2022 and is projected to reach around $450 million by 2028, growing at a compound annual growth rate (CAGR) of about 7%[2].

Growth Drivers

The increasing prevalence of thyroid disorders is a significant driver for the demand of sodium iodide in diagnostics. In the United States alone, approximately 20 million people are affected by thyroid disease, highlighting the need for effective diagnostic solutions[2].

Market Segmentation

The market is segmented into different grades, with the industrial grade segment accounting for a significant share. However, the pharmaceutical grade segment is also growing, driven by the need for high-quality sodium iodide in medical applications[5].

Market Projections

Future Growth

The global sodium iodide market is expected to continue growing, with projections indicating it will reach a valuation of USD 304 million by 2034, growing at a CAGR of 5.8% from 2024 to 2034[5].

Regional Growth

The market in Japan is expected to expand at a CAGR of 6.9% through 2034, driven by increasing demand for diagnostic and therapeutic applications[5].

Sustainability and Innovation

The market is also influenced by trends towards sustainability and environmental responsibility. Manufacturers exploring eco-friendly production methods and packaging for sodium iodide products are likely to gain a competitive edge. Collaborative research and development initiatives between industry players, research institutions, and academic organizations are expected to drive innovation and product development[5].

Applications Beyond Medicine

Water Treatment

Sodium iodide is used in certain water treatment processes for disinfection and decontamination. The demand for iodine-based water treatment solutions is expected to rise, driven by both municipal and industrial sectors, due to increasing concerns about water quality and safety[5].

Aquaculture

Iodine supplementation, including the use of sodium iodide, plays a crucial role in enhancing the health and growth of aquatic species in aquaculture. As aquaculture continues to expand to meet global seafood demand, the use of sodium iodide in this sector is anticipated to grow[5].

Key Takeaways

• Clinical Trials: Sodium iodide I-123 is being tested in various clinical trials for both diagnostic and therapeutic applications, showing promising results in conjunction with NIS gene transfer.
• Market Size: The global sodium iodide market was valued at approximately $300 million in 2022 and is projected to reach around $450 million by 2028.
• Growth Drivers: Increasing prevalence of thyroid disorders and expanding use in diagnostics and therapeutics are key drivers.
• Future Growth: The market is expected to reach a valuation of USD 304 million by 2034, growing at a CAGR of 5.8% from 2024 to 2034.
• Regional Growth: The Japanese market is expected to grow at a CAGR of 6.9% through 2034.
• Sustainability and Innovation: Eco-friendly production methods and collaborative research are expected to drive market growth.

FAQs

Q: What is the primary use of sodium iodide I-123 in medicine?

A: The primary use of sodium iodide I-123 is in diagnostic imaging, particularly for visualizing the thyroid gland and diagnosing thyroid conditions.

Q: How does NIS gene transfer enhance the therapeutic efficacy of sodium iodide I-123?

A: NIS gene transfer allows cells to accumulate radioiodine, which can then be used to treat various cancers by delivering therapeutic doses of I-131.

Q: What is the projected growth rate of the global sodium iodide market?

A: The global sodium iodide market is projected to grow at a CAGR of 5.8% from 2024 to 2034.

Q: What are some non-medical applications of sodium iodide?

A: Sodium iodide is used in water treatment for disinfection and decontamination, and in aquaculture to enhance the health and growth of aquatic species.

Q: How does sustainability impact the sodium iodide market?

A: Manufacturers adopting eco-friendly production methods and packaging are expected to gain a competitive edge, driving market growth and innovation.

Sources

1. ERC: The sodium iodide symporter (NIS): novel applications for...
2. Market Research Intellect: From Diagnostics to Therapeutics: The Growing Sodium Iodide Market
3. Journal of Nuclear Medicine: Phase-1 Clinical Trial Results of High-Specific-Activity Carrier-Free...
4. Theranostics: Sodium Iodide Symporter for Nuclear Molecular Imaging and Gene...
5. GlobeNewswire: Global Sodium Iodide Market to reach a valuation of USD 304 million by 2034 - FMI Projection